Xeris Biopharma (NASDAQ:XERS) Insider Kevin Mcculloch Sells 15,000 Shares of Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Kevin Mcculloch sold 15,000 shares of the stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $8.49, for a total transaction of $127,350.00. Following the transaction, the insider directly owned 1,639,208 shares in the company, valued at approximately $13,916,875.92. This represents a 0.91% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kevin Mcculloch also recently made the following trade(s):

• On Monday, August 3rd, Kevin Mcculloch sold 15,000 shares of Xeris Biopharma stock. The stock was sold at an average price of $8.02, for a total transaction of $120,300.00.
• On Wednesday, July 1st, Kevin Mcculloch sold 90,000 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.03, for a total value of $722,700.00.

Xeris Biopharma Stock Performance

NASDAQ:XERS opened at $8.43 on Wednesday. The firm’s fifty day simple moving average is $8.34 and its 200 day simple moving average is $6.95. Xeris Biopharma Holdings, Inc. has a twelve month low of $5.25 and a twelve month high of $10.08. The company has a quick ratio of 1.02, a current ratio of 1.45 and a debt-to-equity ratio of 17.00. The stock has a market cap of $1.54 billion, a P/E ratio of -76.64 and a beta of 0.66.

Xeris Biopharma (NASDAQ:XERS) last announced its earnings results on Thursday, August 6th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.19). Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 338.21%. The company had revenue of $92.10 million for the quarter, compared to the consensus estimate of $90.12 million. As a group, research analysts predict that Xeris Biopharma Holdings, Inc. will post 0.07 EPS for the current year.

Institutional Investors Weigh In On Xeris Biopharma

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Corient Private Wealth LP bought a new stake in shares of Xeris Biopharma during the 2nd quarter valued at $1,458,000. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in Xeris Biopharma in the 2nd quarter worth approximately $89,000. California State Teachers Retirement System lifted its holdings in Xeris Biopharma by 720.4% in the 2nd quarter. California State Teachers Retirement System now owns 1,479,456 shares of the company’s stock worth $11,717,000 after purchasing an additional 1,299,117 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Xeris Biopharma by 2.9% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 687,632 shares of the company’s stock worth $5,446,000 after purchasing an additional 19,558 shares during the period. Finally, Hsbc Holdings PLC boosted its stake in Xeris Biopharma by 34.0% in the 2nd quarter. Hsbc Holdings PLC now owns 41,779 shares of the company’s stock worth $330,000 after purchasing an additional 10,604 shares during the period. 42.75% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on XERS. Wall Street Zen lowered Xeris Biopharma from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. Barclays raised their price target on shares of Xeris Biopharma from $9.00 to $12.00 and gave the company an “overweight” rating in a research report on Thursday, August 20th. Finally, Weiss Ratings lowered Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Three investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Xeris Biopharma has an average rating of “Hold” and a consensus target price of $12.00.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.